Kasper is a molecular biologist (PhD, Health Sciences) with extensive experience in preclinical drug discovery and platform development. He builds cellular models and assays to generate proof-of-concept data and elucidate mechanism-of-action. His research has centered on RNA and RNA–protein complexes as target and therapeutic modalities, alongside contributions to small-molecule programs across oncology, infectious disease, and metabolic indications.

Before co-founding Biohagen Labs, Kasper was Senior Scientist at Novo Holdings SeedLab (BiOrigin), where he led identification and experimental evaluation of early-stage biotech assets and translated novel science into decision-ready datasets for pharma/biotech partners and investors. Previously, Kasper served as an Assistant Professor at BRIC (University of Copenhagen), where he established screening and validation pipelines for small molecules targeting the cellular translation machinery, combining biochemical assays with proteomics and RNA-seq.

With international research experience across multiple countries, including UC Berkeley, and a strong publication and funding track record, Kasper brings scientific rigor, broad technical range, and clear communication to complex validation work and therapeutic development.